What does erdafitinib treat?

Erdafitinib (Erdafitinib) is a targeted therapy drug mainly used for the treatment of patients with metastatic or locally advanced urothelial cancer (UC) that is sensitive to FGFR (fibroblast growth factor receptor) gene mutations. FGFRGene mutation is a genetic variation associated with the development of cancer, and urothelial cancer involves the bladder, urethra, and renal pelvis. Erdafitinib blocks the growth and division of cancer cells by inhibiting the FGFR signaling pathway, thereby inhibiting the development of tumors. The drug is approved to treat patients with urothelial cancer who have failed traditional treatments, providing a new treatment option for these patients. Although erdafitinib is currently used primarily in urothelial cancer, research and clinical trials may expand its use in other cancer types. Patients should use this medication under the supervision of a physician and receive regular evaluations to ensure optimal treatment.